EGFR and neoplasm: Anti-EGFR IgG3 promoted deposition of C1q and C3b on target tumor cells, as well as generation of upstream C4a, but failed to result in the generation of C3a or C5a due to high expression of CD55 on the tumor cells (72), demonstrating the resistance of cells to terminal complement activation when they express complement regulatory proteins.